700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Settore/i:
Settore:
Impiegati a tempo pieno: 1.543
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer | N/D | N/D | 1968 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
L'ISS Governance QualityScore di Novavax, Inc. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 5; retribuzione: 5.